Inclusion criteria
SCLC, death, anti‐PD‐L2, extensive disease, Cancer
BRAIN METASTASES, METASTASES, SCLC, CANCER
Only patients who meet all of the following criteria will be enrolled in this study:
age ≥18 years and ≤75 years;histologically or cytologically documented extensive disease (American Joint Committee on Cancer Stage [8th edition] IV SCLC [T any, N any, M1 a/b/c]), or T3–4 due to multiple lung nodules that are too extensive or have tumour/nodal volume that is too large to be encompassed in a tolerable radiation plan;brain metastases must be asymptomatic or treated and stable. Patients with suspected brain metastases at screening should have a CT/MRI of the brain prior to study entry;having at least one measurable lesion according to RECIST 1.1;no prior systemic therapy for ES‐SCLC;suitable to receive a platinum (cisplatin or carboplatin) based chemotherapy regimen as first‐line treatment for the ES‐SCLC;ECOG PS score: 0 to 1;life expectancy ≥12 weeks;body weight >30 kg;no prior exposure to immune‐mediated therapy including, but not limited to, other anti‐CTLA‐4, anti‐PD‐1, anti‐PD‐L1 and anti‐programmed cell death ligand 2 (anti‐PD‐L2) antibodies, excluding therapeutic anticancer vaccines;no prior exposure to anti‐angiogenesis drugs;adequate organ and marrow function as defined below:absolute neutrophil count ≥1.5 × 10biochemical test results should meet the following criteria: serum bilirubin ≤1.5 times the upper limit of normal value (ULN); ALT and AST ≤2.5 international normalized ratio (INR) and prothrombin time (PT) ≤1.5 times ULN for patients not receiving therapeutic anticoagulation;women of child‐bearing age should agree to take contraceptive measures (such as intrauterine devices, contraceptives or condoms) during the study and within 6 months after the study; non‐breast‐feeding patients whose serum or urinary pregnancy test should be negative; male patients should agree to take contraceptive measures during the study and within 6 months after the study; andpatients are voluntarily enrolled into the study, sign the informed consent form and have good compliance.